Consistent Tumorigenesis with Self-Assembled Hydrogels Enables High-powered Murine Cancer Studies

Abigail K. Grosskopf¹, Santiago Correa², Julie Baillet², Caitlin L. Maikawa³, Emily C. Gale⁴, Rynne A. Brown⁵, and Eric A. Appel^{2,3,6,7,*}

¹Department of Chemical Engineering, Stanford University, Stanford, CA, 94305, USA

²Department of Materials Science and Engineering, Stanford University, Stanford, CA, 94305, USA

³Department of Bioengineering, Stanford University, Stanford, CA, 94305, USA

⁴Department of Biochemistry, Stanford University, Stanford, CA, 94305, USA

⁵Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA

⁶Department of Pediatrics - Endocrinology, Stanford University, Stanford, CA, 94305, USA

⁷ChEM-H Institute, Stanford University, Stanford, CA, 94305, USA

*Correspondence: eappel@stanford.edu

Abstract

Preclinical cancer research is heavily dependent on allograft and xenograft models, but current approaches to tumor inoculation yield inconsistent tumor formation and growth, ultimately wasting valuable resources (e.g., animals, time, and money) and limiting experimental progress. Here we demonstrate a method for tumor inoculation using self-assembled hydrogels to reliably generate tumors with low variance in growth. The observed reduction in model variance enables smaller animal cohorts, improved effect observation and higher powered studies.

Main Text

A reproducibility crisis in preclinical research has contributed to disappointing outcomes in clinical trials^{1–3}. In response, significant effort has gone into developing animal models that better recapitulate human disease with the hope of improving the predictive power of preclinical research^{4,5}. Yet, little attention has been paid to improving consistency of animal models or developing facile, lab transferable techniques⁶. As a result, inconsistent animal models are endemic and complicate comparisons of data from different labs, within labs, and even within individual experiments⁷. Subcutaneous allograft and xenograft flank models are among the most common models used for preclinical cancer research, particularly for immuno-oncology⁸. These models involve injecting cancerous cells dispersed in liquid buffered saline subcutaneously on the flank of animals and waiting for tumors to form⁹ (Fig. 1a).

Variance in tumor formation necessitates researchers use more animals to conduct sufficiently powered studies, and the chance of failed tumor formation further inflates animal cohort sizes (Fig. 1a). Indeed, technical challenges typically lead to upwards of 30% of inoculated mice failing to form tumors¹⁰. Preclinical cancer studies can involve hundreds of mice, so significant resources, time and animals can be wasted due to the severe inefficiencies present in current model protocols. Since mice with abnormal or late-growing tumors must be euthanized without having contributed useful data to a study, significant ethical concerns are raised by the unnecessary overuse of research animals. Reliable and reproducible models would dramatically reduce the number of mice needed and increase the rate at which discoveries can be made by improving study power.

Current approaches to cancer cell inoculation suffer from two primary drawbacks: (i) inoculation is poorly reproducible animal-to-animal because of cell agglomeration or settling in the syringe prior to injection, and (ii) implanted cells lack extracellular matrix providing critical biochemical and biophysical cues¹¹. Previous reports indicate that cancer cells encapsulated in basement membrane extract (BME, tradenamed Matrigel®) form tumors more rapidly in murine models when compared to cells suspended in saline^{10,12,13}. While these results are promising, BME is a poorly defined solution derived from Engelbreth-Holm-Swarm mouse sarcoma, thereby suffering from considerable batch-to-batch variability, and its temperature-dependent gelation introduces technical difficulties in

Figure 1. Self-assembled hydrogels for preclinical tumor models. **a**, Current method of forming syngeneic subcutaneous tumors by injecting cancerous cells in liquid saline. **b**, Encapsulation process of B16F10 cells in self-assembled hydrogels and the benefits of cell delivery using hydrogels. **c**, Components that form self-assembled hydrogels including cancer cells, alginate, calcium and extracellular matrix-mimicking biopolymers. **d**, Dual syringe mixing strategy to formulate self-assembled hydrogels and encapsulate cells. A 5 wt% polymer solution containing alginate and ECM additives is loaded in one syringe (right) and cells and 250 mM calcium sulfate is loaded into the second syringe (left). Blue dye is included to aid visualization for this demonstration. The two solutions are mixed with a female-female dual syringe mixer by pumping the material back and forth for 30 seconds to form a robust hydrogel pre-loaded into a syringe ready for administration. **e**, Injection of self-assembled hydrogels into a hydrogel depot through syringe needles (25 G). **f**, Oscillatory Shear Temperature ramp ($w=10$ rad/s, $\gamma=1\%$).

avoiding premature gelation within the syringe¹⁴. While BME offers tumorigenic factors like Laminin and Type IV Collagen, the uncertainty of its contents and technically challenging handling provide good reason for researchers to avoid it. There has been increasing interest in the development of alternative, molecularly-defined hydrogel scaffolds for applications in tissue engineering¹⁵. Injectable hydrogels have been developed that can enhance therapeutic cell administration by protecting cells from mechanical forces during injection, enabling homogeneous injections and enhancing cell retention at the injection site^{16,17}. Here we develop a self-assembled hydrogel for controlled encapsulation and delivery of cancer cells that improves the reproducibility of tumor formation. We validate our methods with the widely used B16F10 melanoma model (Fig. 1b).

We use alginate-based hydrogels due to great biocompatibility, and their mild and rapid formation by simple mixing with calcium (Fig. 1c)^{18,19}. This facile fabrication method does not involve complex chemical reactions affording efficient encapsulation of viable cancer cells. These cell-encapsulated injectable hydrogels quickly self-assemble with 30 seconds of mild mixing of two precursor solutions (e.g., alginate and calcium) in a dual-syringe setup that results in the hydrogels pre-loaded in a syringe and ready for injection (Fig. 1d,e, Supplementary Video 1,2). Further, these alginate-based hydrogel formulations can be easily supplemented with laminin (Alg-Lam) and hyaluronic acid (Alg-HA), which are components of the ECM in endogenous tumors^{20,21}. All alginate-based hydrogel formulations display temperature-insensitive dynamic mechanical properties (Fig. 1f, Supplementary Fig. 1). In contrast, BME exhibits irreversible temperature-dependent gelation and much weaker dynamic mechanical properties. For our studies, laminin and HA were added in the maximum quantities possible to formulate consistent alginate-based hydrogels and maintain injectability. Short-term cell viability studies in two commonly used cancer cell lines indicate that the hydrogel formulations are not cytotoxic and that the addition of adhesion motifs such as laminin and HA

Figure 2. Syngeneic tumor model evaluation. a-e, Tumor area measurements over time following inoculation with various formulations containing encapsulated B16F10 cells. Average tumor area and standard deviation, and the corresponding resulting %CV. Supplementary Table 1 displays all p values. Saline exceeded an 100 %CV on Days 10 and 13. Grey lines included to guide the eye for better comparison. f-j, Histology images of tumors excised on day 15 following inoculation with Hemotoxylin&Eosin staining. All scale bars represent 2 mm.

improve cell growth (Supplementary Fig. 2). Different cell lines interestingly demonstrated variable responses to growing in BME.

To demonstrate our method, Luc⁺ B16F10 cancer cells were encapsulated in 50 uL of hydrogel formulations and injected subcutaneously on the flank of C57BL/6 mice through a 21 G needle⁹. Tumor growth was compared with tumors administered in 50 uL of BME and saline. Tumor formation was observed for the first 10 days with *in vivo* imaging (Supplementary Fig. 3,4). Tumors established with saline displayed lower signal on Day 1 than all other formulations, indicating poor cell viability and retention after inoculation, corroborating observations of inconsistent tumor formation reported previously⁹. This initial tumor growth data was additionally fit to a Gompertz model (Supplementary Fig. 5). The fits suggest that our hydrogel approach does not hinder proliferation and may improve end carrying capacity of the tumor compared to saline controls²². Degradation of alginate was also monitored using *in vivo* imaging and fluorescently-labelled alginate. Our results demonstrated that alginate degraded over the course of 10-12 days with a half-life of approximately 4 days (Supplementary Fig. 6, 7). This timescale of degradation aligns with the B16F10 cells growing into a robust tumor, remodelling the matrix and degrading the alginate, suggesting there should not be significant effects of alginate being present during treatment.

Once tumors reached 100 mm², tumor area was measured over time with digital calipers (Fig. 2a-e; Supplementary Fig. 8, Supplementary Table 1). The coefficient of variance (%CV) was quantified (Fig. 2a-e) and revealed that tumors inoculated in a saline vehicle showed the greatest variance among all of the groups evaluated. Tumors formed in BME showed the fastest growth, but also demonstrated a high %CV (40%). Alginate hydrogel alone (Alg) yielded moderate tumor growth with lower %CV (<25%), while the hydrogels comprising tumorigenic ECM components Laminin (Alg-Lam) and HA (Alg-HA) exhibited enhanced tumor growth while maintaining low %CV values (<25% and 15%, respectively) that were less than half that of tumors from saline and BME. The Alg group likely showed the slowest group due to the absence of an additive stimulating tumorigenic biomolecule, like Laminin or Hyaluronic Acid.

Tumor histomorphology on day 15 post-inoculation evaluated by a blinded Pathologist was comparable for tumors

Figure 3. Statistical evaluation of tumor growth, treatment and power. **a**, Percentage of mice that formed palpable tumors during the 15 day experiment. **b**, Treatment day analysis from interpolation assuming exponential growth. Proportion treated from each group over time. **c**, Individual points (representing each mouse's treatment day) plotted with average and standard deviation. **d**, Power analysis predicting the number of mice per group needed based off the experimental data obtained with 80% power. The Statistical toolbox in Matlab was used for power calculations, specifically the *sampsizepwr* function with two-sided t tests. The average and distribution of the day that each formulation surpassed 100 mm² were used in the power analysis. **e**, Power analyses predicting the effect of the tumor area %CV on the number of mice needed per group to obtain 80% power. Dotted lines represent %CV found from experimental formulations. Shading represents the area encompassing the 95% confidence intervals on the %CV values. The high estimate of the 95% confidence interval for both BME and saline exceed 50%. **f**, Power analyses predicting the effect of tumor %CV on the power of the study with 10 mice per group. The dotted colored lines represent the %CV found from experimental formulations. Shading represents the area encompassing the 95% confidence intervals on the %CV values. The high estimate of the 95% confidence interval for both BME and saline exceed 50%.

formed in hydrogel groups (regardless of composition), BME and saline (Fig. 2f-j), suggesting that our delivery method does not change long-term tumor morphology and applicability of tumors formed in hydrogels for preclinical studies. Replicate representative images suggest our delivery method does not change the resulting tumor histomorphology (Supplementary Fig. 9-13). % Necrosis analysis in each tumor and staining with CD31 by a blinded pathologist also suggested comparable angiogenesis and blood supply in all groups (Supplementary Fig. 14-15). Finally, an analysis of lymphocyte infiltration revealed similar numbers of lymphocytes infiltrating the tumors in all groups, except the Alg hydrogel group showed slightly reduced infiltration (Supplementary Fig. 16).

Researchers aim to start treatment when tumors are a given size (e.g., 100 mm²)^{9,10}, which for practical reasons would preferably occur on the same day for all mice; however, treatment must be staggered if tumors grow at different rates. Indeed, 30% of the mice inoculated with cells in saline did not form tumors during the 15 day study (Fig. 3a), corroborating previously reports¹⁰. We therefore analyzed the effect of tumor variance on treatment day by identifying the proportion of mice treated in each group over time using interpolation to predict the day each mouse could be treated (Fig. 3b and Supplementary Fig. 17). The average treatment day and corresponding standard deviation for each formulation were also determined (Fig. 3c), corroborating the variance in tumor growth described above. Tumors inoculated with BME exhibited high variability for time-to-treatment (11.5±1.5 days), highlighting that researchers would have to stagger experimental treatments continuously over the course of 3 to 4 days. In contrast, tumors inoculated in Alg-Lam and Alg-HA hydrogels exhibited lower variability (12.7±0.9 day and 11.9±1.0 day, respectively), resulting in a more convenient treatment schedule and likely improving the precision of treatments.

Reduced model variance reduces type II error, allowing researchers to use fewer animals and observe differences between treatments with higher power. Assuming that the variance in tumor areas due to the model at the start

of treatment is representative of the variance throughout treatment, it is possible to determine the impact of the improved model on design of sufficiently powered studies (Fig. 3d-f). The reduction in the tumor variance observed with Alg-HA hydrogels compared to saline and BME results in a dramatic reduction in the number of mice required to observe differences between treatments. We performed calculations with only best performing the Alg-HA hydrogel group and control groups to reduce the number of groups and complexity in this power analysis. For example, to observe a 30% difference between means of two treatment groups with 80% power, an Alg-HA-based B16F10 model would require approximately 80% fewer mice than a BME-based model (Fig. 3d, Supplementary Fig. 18). A reduction in model variance therefore reduces the number of mice required for sufficiently powered preclinical cancer studies. Alternatively, if researchers plan to use 10 mice in each experimental group (a typical group size⁴), an Alg-HA-based model would enable observation of significant differences between groups down to effect sizes of only 21%, whereas a BME-based model would only permit observations of effect sizes larger than 56% (Fig. 3e). The reduced variance of alginate-based tumor models can therefore enable the observation of more subtle effects and may lead researchers to important discoveries that would otherwise be missed. If researchers plan to use 10 mice per group, a decrease in model variance yields much higher powered studies. In a study evaluating a 30% effect size in 10 mice, a Alg-HA-based model enables a 60% increase in power over a BME-based model (Fig. 3f).

Our method has the capacity to enhance the reliability of tumor formation and consistency of tumor growth for the widely used B16F10 model, demonstrating an opportunity to improve preclinical cancer models to aid observation, increase study power, and reduce resource usage (*i.e.*, fewer mice and less researcher time). The hydrogel encapsulation procedure we demonstrate here, which only requires a simple mixing step using commercially available precursors and standard supplies, is accessible to all preclinical cancer researchers. We show improved results over current methods that utilize either saline or BME. While extensive research has focused on developing biomaterials for tissue engineering applications, the use of biomaterials to generate more reproducible *in vivo* cancer models has not been extensively explored. We demonstrate here, using predictive modeling, that a biomaterials-enhanced cancer model can reduce technical burden and simplify study design.

Methods

Hydrogel Formation by Self-assembly

Hydrogels were prepared using a dual syringe mixing technique. Briefly, a stock solution of sterile Alginate (Pronova UP LVG), (5 wt%) was prepared by adding saline to the polymers and allowing them to dissolve over 1 day at 4°C. This alginate is higher in G content, leading to reduced immunogenicity¹⁸. A stock solution of alginate (5 wt%) and hyaluronic acid (HA) (Lifecore Biomedical, 1.5 MDA, 1.25 wt%) was also prepared in saline. Biopolymer stock solutions were loaded into one syringe at the volume needed to reach the desired final concentration (1 wt% polymer total, and 10 mM calcium). A stock solution of calcium sulfate (250 mM) was prepared in water in a large container in the form of a slurry. The calcium sulfate stock solution was stirred vigorously and quickly added to an eppendorf tube containing cells and saline. Laminin Mouse Protein (ThermoFisher) was added to the solution containing calcium and cells to a final concentration of 1 mg/mL. HA was added to a final concentration of 20 mg/mL. The stock solution of calcium and cells was then moved to a luer lock 1 mL syringe. The syringes containing the two stock solutions were then connected using a female-female luer lock mixer and the gels were prepared by mixing for 30 pumps. Once mixed, the cell-loaded hydrogels were pushed into one of the syringes, which was then removed from the luer lock mixer and equipped with a needle for application.

Conjugation of Cyanine7 Fluorescent Dye to Alginate

Fluorescent alginate was prepared using carbodiimide chemistry according to established protocols^{23,24} whereby Sulfo-Cyanine7 amine (5 mg, 0.0062 mmol; Lumiprobe) was dissolved under stirring in 15 mL of an alginate solution (10 mg/mL⁻¹) formed in 0.1 M MES buffer at pH 6 (ThermoFisher). Sulfo-NHS (41 mg, 0.19 mmol; Biovision) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC; 72.5 mg, 0.38 mmol; SigmaAldrich) were successively added, and the reaction mixture was stirred at room temperature for 20 hours. The crude product was dialyzed against deionized water for three days (3.5 kDa MWCO) and lyophilized until dried.

Rheological Characterization

Rheological testing was performed using a 20 mm diameter serrated parallel plate at a 750 μ m gap on a stress-controlled TA Instruments DHR-2 rheometer. All experiments were performed at 37°C to be representative of physiological conditions. Frequency sweeps were performed at a strain of 1%. Temperature sweeps were performed

at a strain of 1% and a frequency of 10 rad/s. Amplitude sweeps were performed at frequency of 10 rad/s. Independent hydrogel formulations were mixed for each test.

B16F10 Cell Culture

Luc⁺ B16F10 cells were purchased from ATCC (ATCC CRL-6475-LUC2). They were cultured in Dulbecco's Modified Eagle Media (DMEM) containing 10% FBS, 1% Penicillin-Streptomycin, and, if Luc⁺, with 10 ug/mL Blasticidin. Cells were split at a 1:5 ratio every three days when approximately 80% confluent. For *in vivo* experiments, they were injected at passage 3 when 50% confluent. Cells tested negative for mycoplasma using Lonza MycoAlert Mycoplasma Detection Kit prior to experiments.

EG7 Cell Culture

EG7 cells were purchased from ATCC. They were cultured in RPMI media containing 10% FBS, 1% Penicillin-Streptomycin, and 0.05 mM 2-mercaptoethanol. Cell media was supplemented every two days and upon confluency (1e6 cells/mL), cells were split by dilution to a seeding density of 100,000 cells/mL. Cells tested negative for mycoplasma using Lonza MycoAlert Mycoplasma Detection Kit prior to experiments.

Short-term Viability Assay

Promega CellTiter-Glo 3D Cell Viability Assay was used to characterize the short-term cell viability in different formulation conditions. Cells were seeded between 5,000-10,000 cells per well in an opaque 96 well plate in 100 uL of media or gel per well. Relative viability was measured after 1 day in culture by adding 100 uL per well of the CellTiter-Glo reagent, mixing for 5 minutes, allowing the plate to sit for 25 minutes, and then reading the luminescent signal with a 1 second integration time.

***In Vivo* Tumor Growth Experimental Set-Up**

Luc⁺ B16F10 cells (Passage 3) were administered to each mouse subcutaneously on the flank in a volume of 50 μ L volume containing 400,000 cells using a 1 mL luer-lock syringe with a 21 G needle. 400,000 cells was chosen as an intermediate number of cells based on previously reported protocols⁹. Immunocompetent female C57BL/6 mice from Charles River Laboratory (6-8 weeks) were used for all experiments. All experiments followed protocols approved by the Stanford Administrative Panel on Laboratory Animal Care. Each group contained 9 or 10 replicates (n=10 for saline, BME, Alginate and Alg-Lam; n=9 for Alg-HA). Experimental groups were blinded and randomized by cage. Hydrogel formulations comprising encapsulated cells were prepared in syringes in the laboratory 30 minutes prior to inoculation. Cell suspensions were prepared in saline or basement membrane extract and kept on ice prior to loading into syringes immediately before inoculation. Double the amount of saline volume was prepared to follow established procedures to prevent cell aggregation in the syringe⁹.

Murine Tumor Growth Experiment

For the first 10 days of *in vivo* tumor growth experiments, an *In Vivo* Imaging System (Lago) was used to monitor tumor progression. Firefly luciferin was delivered subcutaneously (150 mg/kg mouse body weight) in 200 uL injection volumes. Luciferase has been found to have immunogenic effects in certain models and was equally used for imaging in all groups for experiments, so side-effects should be uniform among groups²⁵. After waiting 10 minutes, images were recorded with an exposure of 30 seconds every 5 minutes for a period of 15 minutes until maximum flux was reached. Total flux of photons in the tumor region of interest (ROI) was used to quantify tumor growth. Aura imaging software was used to collect and analyze data. Starting on Day 10 following tumor inoculation, tumors were measured on each mouse using digital calipers. An area was calculated using length and width caliper measurements. The percent coefficient of variance was calculated as the standard deviation divided by the mean.

Fit of *In vivo* Imaging Data to the Gompertz Model

In vivo imaging data for all groups was fit to the Gompertz model equation (see Supplementary Fig. 4) using GraphPad Prism. Fits were applied on days 3-10 because the administration impacted the initial growth curve on days 1-3. Initial tumor sizes ($X(0)$) for all groups were extrapolated to time zero for the fit to approximately 100-fold lower than the tumor signal observed on day 3.

***In vivo* Alginate Degradation**

Hydrogels were formulated as previously described though comprising 0.2 wt% Cy7-labelled alginate and 0.8 wt% plain alginate. B16F10 cells were encapsulated and injected in the hydrogels as described previously. Alginate

degradation was monitored using an *in vivo* imaging system and quantified as the total photons in the region of interest (ROI) surrounding the tumor. An exposure of 1 second was used to collect images with an excitation/emission of 720/790 nm.

Treatment Day Analysis

The treatment day was calculated for each mouse by interpolating between two timepoints to when the tumor area reached 100 mm². Interpolation was performed assuming both exponential and linear tumor growth. The average treatment day and standard deviation for each group were calculated from the individual mice. Mice that required extrapolation before day 9 and after day 16 (tumor reached 100 mm² before measurement began or after measurements stopped) were removed from the analysis. The following equations describe the linear interpolation approach, where t_{100} represents the day when the tumor reaches 100 mm², A_1 , A_2 represent area measurements for corresponding days t_1 and t_2 ,

$$t_{100} = \frac{\ln(100) - b}{a}$$

where

$$a = \frac{\ln(A_2) - \ln(A_1)}{t_2 - t_1}$$

and

$$b = \ln(A_2) - a * t_2.$$

When making the Kaplan-Meier type plot, the treatment day was recorded at the whole number day after a calculated treatment time. The average treatment day was found by averaging individual treatment days. Saline was excluded from this analysis due to the high percentage of mice that never formed tumors.

Histology and Analysis

Tumors were explanted 15 days after inoculation, immersed in formalin for 72 hours and then 70% ethanol for 48 hours. Tumor specimens were sliced and stained with H&E, CD3, and CD31 by Stanford Animal Histology Services. All samples were analyzed by a blinded pathologist. For analysis of lymphocyte infiltration, 10 high power images were taken at all areas of each tumor. Lymphocytes (stained dark brown with a clear circumference) were manually counted in each photo with the FIJI Cell-Counter plug-in.

Power Analysis

The Statistical toolbox in Matlab was used for power calculations, specifically the *sampsizepwr* function with two-sided t tests. For calculations based off experimental data, the average and distribution of the day that each formulation surpassed 100 mm² were used in the power analysis. Because 30% of the saline tumors did not form at all during the experiment, these mice were excluded from this analysis, leading the saline group to require less mice than the BME group in the power analysis. Here the effect size was calculated as a observed percent change from the formulation average of 100 mm² in 1% intervals to predict the number of mice needed. For calculations predicting the effect of the coefficient of variance on the number of mice, the variance was calculated as a percent change from 100 mm² in 1% intervals with a constant 80% power. For calculations predicting the effect of variance on the power of the study, the variance was calculated as a percent change from 100 mm² in 1% intervals with a constant 10 mouse per group sample size. Example code is shown in the supplemental information. Code can be shared upon reasonable request.

Statistical Treatment to find Confidence Intervals on %CV

Confidence intervals in %CV values were calculated using Vangel's modification to McKay's method, which assumes the data is approximately normal and starts giving less valuable estimates as the %CV exceed 33%²⁶. To summarize this calculation, the lower (*lcl*) and upper limits (*ucl*) were calculated as,

$$lcl = \frac{K}{\sqrt{(\frac{u_1+2}{n} - 1) * K^2 + \frac{u_1}{n-1}}},$$

$$ucl = \frac{K}{\sqrt{(\frac{u_2+2}{n} - 1) * K^2 + \frac{u_2}{n-1}}},$$

where

$$u_1 = \chi^2_{1-\alpha/2, n-1}$$

and

$$u_2 = \chi^2_{\alpha/2, n-1}.$$

K represents a sample %CV, n is the number of samples, and χ^2_{α} represents the chi squared distribution at the designated confidence α .

Competing interests

A provisional patent has been filed on these findings.

Author's contributions

A.K.G. and E.A.A. conceived of the idea and planned experiments. A.K.G. performed experiments. S.C. helped with experimental planning and setting up experiments. R.A.B. and C.L.M. aided in analysis of experimental data and statistical methods. E.C.G. helped perform experiments. All authors contributed to the final manuscript.

References

1. Day, C.-P., Merlino, G. & Dyke, T. V. Preclinical mouse cancer models: A maze of opportunities and challenges. *Cell* **163**, 39 – 53, DOI: <https://doi.org/10.1016/j.cell.2015.08.068> (2015).
2. Landis, S. C. *et al.* A call for transparent reporting to optimize the predictive value of preclinical research. *Nature* **490**, 187–191 (2012).
3. Mak, I. W., Evaniew, N. & Ghert, M. Lost in translation: animal models and clinical trials in cancer treatment. *American journal translational research* **6**, 114 (2014).
4. Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. *Nature Reviews Cancer* **7**, 654–658 (2007).
5. Martin, D. S. *et al.* Role of murine tumor models in cancer treatment research. *Cancer research* **46**, 2189–2192 (1986).
6. Cibelli, J. *et al.* Strategies for improving animal models for regenerative medicine. *Cell stem cell* **12**, 271–274 (2013).
7. Shaw, R., Miller, S., Curwen, J. & Dymond, M. Design, analysis and reporting of tumor models. *Lab animal* **46**, 207 (2017).
8. Mosely, S. I. *et al.* Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. *Cancer immunology research* **5**, 29–41 (2017).
9. Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. *Current Protocols Immunology* **39**, 20.1.1–20.1.29, DOI: [10.1002/0471142735.im2001s39](https://doi.org/10.1002/0471142735.im2001s39) (2000). <https://currentprotocols.onlinelibrary.wiley.com/doi/pdf/10.1002/0471142735.im2001s39>.
10. Fridman, R., Benton, G., Aranoutova, I., Kleinman, H. K. & Bonfil, R. D. Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (cultrex or matrigel) co-injection. *nature protocols* **7**, 1138–1144 (2012).
11. Foster, A. A. *et al.* Protein-engineered hydrogels enhance the survival of induced pluripotent stem cell-derived endothelial cells for treatment of peripheral arterial disease. *Biomaterials science* **6**, 614–622 (2018).
12. Fridman, R. *et al.* Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with matrigel. *JNCI: Journal National Cancer Institute* **83**, 769–774 (1991).
13. Fridman, R. *et al.* Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. *Proceedings National Academy Sciences* **87**, 6698–6702 (1990).
14. Benton, G., Arnaoutova, I., George, J., Kleinman, H. K. & Koblinski, J. Matrigel: from discovery and ecm mimicry to assays and models for cancer research. *Advanced drug delivery reviews* **79**, 3–18 (2014).

15. Aisenbrey, E. A. & Murphy, W. L. Synthetic alternatives to matrigel. *Nature Reviews Materials* 1–13 (2020).
16. Lopez Hernandez, H., Grosskopf, A. K., Stapleton, L. M., Agmon, G. & Appel, E. A. Non-newtonian polymer–nanoparticle hydrogels enhance cell viability during injection. *Macromolecular bioscience* **19**, 1800275 (2019).
17. Grosskopf, A. K. *et al.* Injectable supramolecular polymer–nanoparticle hydrogels enhance human mesenchymal stem cell delivery. *Bioengineering & Translational Medicine* **5**, e10147 (2020).
18. Lee, K. Y. & Mooney, D. J. Alginate: properties and biomedical applications. *Progress polymer science* **37**, 106–126 (2012).
19. Wisdom, K. & Chaudhuri, O. 3d cell culture in interpenetrating networks of alginate and rbm matrix. In *3D Cell Culture*, 29–37 (Springer, 2017).
20. Misra, S. *et al.* Hyaluronan–cd44 interactions as potential targets for cancer therapy. *The FEBS journal* **278**, 1429–1443 (2011).
21. Terranova, V., Llotta, L., Russo, R. G. & Martin, G. Role of laminin in the attachment and metastasis of murine tumor cells. *Cancer Research* **42**, 2265–2269 (1982).
22. Xu, X. The biological foundation of the gompertz model. *International journal bio-medical computing* **20**, 35–39 (1987).
23. Chaudhuri, O., Cooper-White, J., Janmey, P. A., Mooney, D. J. & Shenoy, V. B. Effects of extracellular matrix viscoelasticity on cellular behaviour. *Nature* **584**, 535–546 (2020).
24. Rowley, J. A., Madlambayan, G. & Mooney, D. J. Alginate hydrogels as synthetic extracellular matrix materials. *Biomaterials* **20**, 45–53 (1999).
25. Day, C.-P. *et al.* “glowing head” mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts. *PloS one* **9**, e109956 (2014).
26. Vangel, M. G. Confidence intervals for a normal coefficient of variation. *The American Statistician* **50**, 21–26 (1996).